RNS Number : 9003E
Ergomed plc
11 November 2020
RNS REACH
PRESS RELEASE
Ergomed to Present at Jefferies Virtual London Healthcare Conference
Guildford, UK - 11 November 2020:
Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces that Richard Barfield, Chief Financial Officer of Ergomed, will present at the Jefferies Virtual London Healthcare Conference at 11am GMT on 17 November 2020.
A live webcast of the presentation will be available on Ergomed's website, here:
https://www.ergomedplc.com/investor-relations/reports-and-presentations/
ENDS
Enquiries:
|
Ergomed plc
|
Tel: +44 (0) 1483 402 975
|
|
Miroslav
Reljanović
(Executive Chairman)
|
|
|
Richard Barfield (Chief Financial Officer)
|
|
|
|
|
|
Numis Securities Limited
|
Tel: +44 (0) 20 7260 1000
|
|
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
|
|
|
James Black (Broker)
|
|
|
|
|
|
Consilium Strategic Communications - for UK enquiries
|
Tel: +44 (0) 20 3709 5700
|
|
Chris Gardner / Sue Stuart
|
ergomed@consilium-comms.com
|
|
Matthew Neal / Olivia Manser
|
|
|
|
|
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit:
http://ergomedplc.com
.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
NRAFFWFASESSESF
|
